万春药业公布Dublin-3 III期研究的新分析结果,显示Plinabulin + Docetaxel在抗Pd-(L)1治疗后对于非鳞状EGFR野生型NSCLC的生存获益,以及与Docetaxel相比脑转移减少情况,在NACLC 2025上发布

美股速递
Dec 11

万春药业公布Dublin-3 III期研究的新分析结果,显示Plinabulin + Docetaxel在抗Pd-(L)1治疗后对于非鳞状EGFR野生型NSCLC的生存获益,以及与Docetaxel相比脑转移减少情况,在NACLC 2025上发布

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10